FDA WARNING_LETTER - Mindray DS USA, Inc. d.b.a. Mindray North America - August 02, 2012

On June 11, 2012, through August 02, 2012, the FDA inspected Mindray DS USA, Inc. in Mahwah, New Jersey, and found that the firm's Class II medical devices, including patient monitors, chemistry analyzers, and ultrasound systems, were adulterated. The manufacturing, packing, storage, or installation methods and controls did not conform to Current Good Manufacturing Practice (cGMP) requirements of the Quality System (QS) regulation (21 CFR Part 820).

Key violations included: 1. **Failure to adequately establish procedures for corrective and preventive action (CAPA)** (21 CFR 820.100(a)). Examples include unaddressed V-Series monitor touchscreen failures, cracked bezels on DPM 6/Beneview T5 Patient Monitors, inadequate CAPA investigations for failed NIBP modules in Spectrum, Passport V, and Passport 2 Monitors, and failed disclosure drives in Panorama Monitors. Additionally, CAPA effectiveness verification was not documented for DPM Central Station software anomalies and DPM 6/7 Monitor software upgrade issues. The firm's response was deemed inadequate as it lacked specific data.

2. **Failure to review, evaluate, and investigate complaints** (21 CFR 820.198(c)). Written procedures did not require investigation of device, labeling, or packaging failures. Specific instances included uninvestigated software upgrade